MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

retatrutide

  • Home
  • retatrutide
Retatrutide Produces Broad Favorable Shifts in Fatty Acid Oxidation and Insulin Resistance Biomarkers in Obesity With or Without Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Retatrutide Produces Broad Favorable Shifts in Fatty Acid Oxidation and Insulin Resistance Biomarkers in Obesity With or Without Type 2 Diabetes

Posted by By MedXY 05/16/2026
Post-hoc metabolomic and lipidomic analyses from two phase 2 trials suggest retatrutide favorably remodels metabolic pathways linked to fatty acid oxidation, insulin resistance, and triglyceride composition in obesity, with and without type 2 diabetes.
Read More
Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Posted by By MedXY 08/02/2025
Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.
Read More
  • Enhanced Risk Stratification for Pediatric Tracheostomy Hospitalizations: Evaluating a Novel Tracheostomy-Specific Tier System
  • Long-Term Outcomes of Dysphagia Following Type I Laryngeal Cleft Repair in Children
  • Inadvertent Parathyroidectomy During Thyroid Surgery: Incidence, Risk Factors, and Clinical Implications
  • Understanding Surgical Faculty Retention: Key Factors Influencing Their Decision to Stay or Leave
  • Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis: Insights from the 24-Month LIMS Study Follow-Up
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top